8-K current report · filed Nov 9, 2026

Stryker Corporation (SYK) 8-K Current Report: November 9, 2026

Item 5.02Item 7.01Item EX-99.1SYK overview

Short answer

Stryker Corporation (SYK) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive.

Stryker Corporation 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive
  • James E. Davis joins effective January 1, 2027, bringing CEO experience at Quest Diagnostics and prior medical-device leadership
  • No Board committee assignment initially, limiting immediate influence over audit, compensation or governance functions
  • Compensation aligned with Stryker’s other nonemployee directors, with standard director indemnification protections

Item 7.01 · Regulation FD Disclosure

  • Stryker elected Mr. Davis to its board, expanding or changing board oversight
  • Exhibit 99.1 contains the company’s announcement and related director details

Item EX-99.1 · Exhibit EX-99.1

  • Board nomination of Jim Davis effective January 1, 2027, pending election
  • Davis brings CEO experience at Quest Diagnostics and prior leadership of GE’s MRI business
  • Medical technology and global healthcare expertise strengthens board oversight of Stryker’s strategy
  • Leadership addition relevant to investors, but no immediate financial impact or compensation terms disclosed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Stryker Corporation 8-K filings

Get the next SYK 8-K as it lands

Follow SYK for push alerts, or ask the research agent what this filing means.